Real-world effectiveness of pembrolizumab for first-line treatment of metastatic non-small-cell lung cancer: a decade of evidence and experience.

Babel RA, Liu SV, Fan T, Amonkar MM, Velcheti V

Open source

DOI
10.1080/14796694.2026.2709201
Published
2026 Aug
Container
Future oncology (London, England)
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1080/14796694.2026.2709201,
  title = {Real-world effectiveness of pembrolizumab for first-line treatment of metastatic non-small-cell lung cancer: a decade of evidence and experience.},
  author = {Babel RA and Liu SV and Fan T and Amonkar MM and Velcheti V},
  year = {2026},
  journal = {Future oncology (London, England)},
  doi = {10.1080/14796694.2026.2709201},
  url = {https://doi.org/10.1080/14796694.2026.2709201}
}

RIS

TY  - JOUR
TI  - Real-world effectiveness of pembrolizumab for first-line treatment of metastatic non-small-cell lung cancer: a decade of evidence and experience.
AU  - Babel RA
AU  - Liu SV
AU  - Fan T
AU  - Amonkar MM
AU  - Velcheti V
PY  - 2026
JO  - Future oncology (London, England)
DO  - 10.1080/14796694.2026.2709201
UR  - https://doi.org/10.1080/14796694.2026.2709201
ER  - 

APA

RA, B., SV, L., T, F., MM, A., & V, V. (2026). Real-world effectiveness of pembrolizumab for first-line treatment of metastatic non-small-cell lung cancer: a decade of evidence and experience.. Future oncology (London, England). https://doi.org/10.1080/14796694.2026.2709201

Source records